Myriad Genetics Q3 revenue $205.7M (-4% YoY); GAAP net loss $0.29/sh, adj EPS $0.00; FY guidance reiterated

MYRIAD GENETICS INC

2025-Q3 EPS reported -$3.88 revenue$614,700,000

Q3 revenue $205.7M, down 4% YoY; flat excluding $8.1M in headwinds from UNH GeneSight coverage loss and EndoPredict divestiture.
GAAP net loss $27.4M ($0.29 per share); adjusted EPS $0.00; adjusted EBITDA $10.3M.
Hereditary cancer testing volume +11% YoY, revenue +3%; pharmacogenomics revenue -19% due to UnitedHealthcare coverage discontinuation.
Gross margin 69.9%; cash and equivalents $145.4M as of Sept 30, 2025.
Entered strategic collaboration with SOPHiA GENETICS for global liquid biopsy companion diagnostic development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.